ondansetron has been researched along with Vascular Diseases in 1 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Vascular Diseases: Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Childs, AM | 1 |
| Coates, AS | 1 |
| Cox, KM | 1 |
| Mainwaring, PN | 1 |
1 other study available for ondansetron and Vascular Diseases
| Article | Year |
|---|---|
Severe vascular adverse effects with thrombocytopenia and renal failure following emetogenic chemotherapy and ondansetron.
Topics: Adult; Antineoplastic Agents; Emetics; Female; Humans; Male; Ondansetron; Renal Insufficiency; Throm | 1994 |